$VTAE Wedbush Reiterates “Outperform” Ratin
Post# of 22707
![Avatar](/images/ProfileImages/984076804_464_129571309_0017.gif)
Wedbush Reiterates “Outperform” Rating for Vitae Pharmaceuticals Inc (VTAE)
Posted by paymon on Mar 7th, 2016 // No Comments
Vitae Pharmaceuticals logoVitae Pharmaceuticals Inc (NASDAQ:VTAE)‘s stock had its “outperform” rating reiterated by equities researchers at Wedbush in a research note issued to investors on Thursday, MarketBeat Ratings reports. They currently have a $20.00 price target on the stock. Wedbush’s price target suggests a potential upside of 326.44% from the stock’s current price.
VTAE has been the topic of a number of other research reports. Piper Jaffray reaffirmed a “buy” rating and set a $23.00 target price (up previously from $18.00) on shares of Vitae Pharmaceuticals in a report on Monday, January 4th. Zacks Investment Research downgraded Vitae Pharmaceuticals from a “hold” rating to a “sell” rating in a report on Tuesday, November 10th. Wells Fargo started coverage on Vitae Pharmaceuticals in a report on Thursday, December 3rd. They issued an “outperform” rating on the stock. Finally, Stifel Nicolaus reissued a “buy” rating and issued a $22.00 price target on shares of Vitae Pharmaceuticals in a report on Wednesday, December 30th. Three research analysts have rated the stock with a hold rating and three have given a buy rating to the company. The company currently has a consensus rating of “Buy” and an average target price of $21.00.
Vitae Pharmaceuticals (NASDAQ:VTAE) opened at 4.69 on Thursday. Vitae Pharmaceuticals has a one year low of $4.15 and a one year high of $18.71. The company’s 50-day moving average price is $9.53 and its 200-day moving average price is $12.14. The firm’s market cap is $102.57 million.
Vitae Pharmaceuticals (NASDAQ:VTAE) last released its earnings results on Thursday, March 3rd. The company reported ($0.52) EPS for the quarter, topping analysts’ consensus estimates of ($0.62) by $0.10. The firm had revenue of $0.09 million for the quarter, compared to the consensus estimate of $0.14 million. During the same period in the prior year, the business earned ($0.40) EPS. The company’s quarterly revenue was down 42.9% on a year-over-year basis. On average, analysts anticipate that Vitae Pharmaceuticals will post ($2.21) EPS for the current year.
A number of hedge funds have bought and sold shares of the stock. Ghost Tree Capital LLC boosted its stake in Vitae Pharmaceuticals by 10.0% in the fourth quarter. Ghost Tree Capital LLC now owns 275,000 shares of the company’s stock valued at $4,978,000 after buying an additional 25,000 shares in the last quarter. Boxer Capital LLC purchased a new position in shares of Vitae Pharmaceuticals during the fourth quarter valued at about $4,530,000. D. E. Shaw & Co. Inc. boosted its position in shares of Vitae Pharmaceuticals by 68.3% in the fourth quarter. D. E. Shaw & Co. Inc. now owns 203,462 shares of the company’s stock valued at $3,683,000 after buying an additional 82,539 shares during the period. Millennium Management LLC boosted its position in shares of Vitae Pharmaceuticals by 15.2% in the fourth quarter. Millennium Management LLC now owns 873,436 shares of the company’s stock valued at $15,809,000 after buying an additional 114,981 shares during the period. Finally, Balyasny Asset Management LLC purchased a new position in shares of Vitae Pharmaceuticals during the fourth quarter valued at about $2,096,000.
In related news, CEO Jeffrey S. Hatfield sold 22,524 shares of the firm’s stock in a transaction that occurred on Wednesday, December 23rd. The stock was sold at an average price of $17.00, for a total value of $382,908.00. Following the sale, the chief executive officer now directly owns 293,897 shares in the company, valued at approximately $4,996,249. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. Also, Director Donald J. Hayden, Jr. sold 16,130 shares of the firm’s stock in a transaction that occurred on Tuesday, December 29th. The shares were sold at an average price of $18.00, for a total value of $290,340.00. The disclosure for this sale can be found here.
Vitae Pharmaceuticals, Inc is a clinical stage biotechnology company focused on discovering and developing small molecule drugs for diseases where there are unmet medical needs. The Company is developing a portfolio of product candidates generated by Contour, its structure-based drug discovery platform.
12 Month Chart for NASDAQ:VTAE
Frustrated with your broker? Are you tired of paying high fees? Do you feel like you are getting ripped off by your stock broker? It's time for a change. Find out which brokerage is best for your personal trading style at the InvestorPlace Broker Center. Compare brokers at a glance in the InvestorPlace Broker Center (Click Here).
Receive News & Ratings for Vitae Pharmaceuticals Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Vitae Pharmaceuticals Inc and related companies with MarketBeat.com's FREE daily email newsletter.
![Like This Post](/images/thumb-up.png)
![Dislike This Post](/images/thumb-down.png)
NASDAQ DIP and RIP
Here is the best word that describes what i do here.
Intuitive;
means having the ability to understand or know something without any direct evidence or reasoning process.
I was born with it, I'm truly blessed!
Alway's searching for winners'
![937206596_images.jpg](https://investorshangout.com/images/MYImages/937206596_images.jpg)